Radiopharm Theranostics (RADX) - Long-Term Debt to Capital

The growth of Radiopharm Theranostics (RADX) is driven by advancements in radiopharmaceutical development and FDA approvals. The long-term debt-to-equity ratio demonstrates financial stability, with the current level standing at 0.00. Strict nuclear regulations and isotope delivery patents create a high barrier to entry. The business operates within a closed biotech environment, where patients are fully tied to specialized medical centers.

The diversified radiopharmaceutical pipeline of Radiopharm Theranostics (RADX) requires significant investment in long-term development. The long-term debt-to-equity ratio reflects the share of loans with a maturity of over one year within the financing structure. This metric compares long-term liabilities to the market value of equity to measure the level of financial leverage. An increase in this indicator signals a rising debt burden, while consistently low values confirm high solvency and the reliability of the asset.